Home » Stocks » GTH

Genetron Holdings Limited (GTH)

Stock Price: $20.09 USD -1.16 (-5.46%)
Updated Jan 15, 2021 4:00 PM EST - Market closed
After-hours: $20.49 +0.40 (1.99%) Jan 15, 4:55 PM
Market Cap 1.78B
Revenue (ttm) 46.20M
Net Income (ttm) -96.58M
Shares Out 441.81M
EPS (ttm) -3.86
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 15
Last Price $20.09
Previous Close $21.25
Change ($) -1.16
Change (%) -5.46%
Day's Open 21.25
Day's Range 19.98 - 21.42
Day's Volume 385,851
52-Week Range 9.10 - 21.42

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
Business Wire - 2 days ago

BEIJING--(BUSINESS WIRE)--Genetron Holdings Limited (“Genetron Health” or the “Company”, Nasdaq: GTH), a leading precision oncology platform company in China that specializes in offering molec...

Business Wire - 1 week ago

NANJING, China--(BUSINESS WIRE)--Genetron Holdings Limited (“Genetron Health” or the “Company”) (Nasdaq: GTH), a leading precision oncology company in China that specializes in offering molecu...

Seeking Alpha - 1 month ago

Genetron Health, a Beijing-North Caroline diagnostic company, announced a city-wide early screening test for liver cancer in Wuxi city using the company's blood-based HCCscreen. Sinopharm has ...

Other stocks mentioned: SHTDY
Business Wire - 1 month ago

BEIJING--(BUSINESS WIRE)--Genetron Holdings Limited (“Genetron Health” or the “Company”, Nasdaq: GTH), a leading precision oncology platform company in China that specializes in offering molec...

Business Wire - 1 month ago

BEIJING--(BUSINESS WIRE)--The global COVID-19 pandemic has highlighted the critical importance of early detection and intervention in fighting other life-threatening diseases, such as cancer, ...

Business Wire - 1 month ago

BEIJING--(BUSINESS WIRE)--Genetron Holdings Limited (“Genetron Health” or the “Company”, Nasdaq: GTH), a leading precision oncology platform company in China that specializes in offering molec...

GlobeNewsWire - 2 months ago

BEIJING, Nov. 12, 2020 (GLOBE NEWSWIRE) -- Genetron Holdings Limited (“Genetron Health” or the “Company”, NASDAQ: GTH), a leading precision oncology platform company in China that specializes ...

Seeking Alpha - 2 months ago

Genetron Holdings went public in June 2020 and just reported its Q3 2020 results. The firm provides a range of cancer diagnostic and monitoring services in China.

GlobeNewsWire - 2 months ago

BEIJING, Nov. 09, 2020 (GLOBE NEWSWIRE) -- Genetron Holdings Limited (“Genetron Health” or the “Company”, NASDAQ:GTH), a leading precision oncology platform company in China that specializes i...

GlobeNewsWire - 2 months ago

BEIJING, Oct. 29, 2020 (GLOBE NEWSWIRE) -- Genetron Holdings Limited (“Genetron Health” or the “Company”, Nasdaq: GTH), a leading precision oncology platform company in China that specializes ...

GlobeNewsWire - 2 months ago

BEIJING, China, Oct. 26, 2020 (GLOBE NEWSWIRE) -- Genetron Holdings Limited (“Genetron Health” or the “Company”, NASDAQ:GTH), a leading precision oncology platform company in China that specia...

GlobeNewsWire - 2 months ago

Collaboration and equity investment to provide Genetron Health with significant know-how in immune profiling and accelerate MRD product development in hematologic cancer Collaboration and equi...

GlobeNewsWire - 3 months ago

Designation represents Genetron Health’s first step to potentially expand the geographical reach of HCCscreen™ Designation represents Genetron Health’s first step to potentially expand the geo...

Seeking Alpha - 3 months ago

China has a considerably large gene pool, a decisive success factor in conducting prospective research in early-stage cancer studies. Local bureaucracy has the power to lead nationwide research.

GlobeNewsWire - 3 months ago

BEIJING and SUZHOU, China, Sept. 25, 2020 (GLOBE NEWSWIRE) -- Genetron Holdings Limited (“Genetron Health”, Nasdaq: GTH), a leading precision oncology platform company in China that speciali...

GlobeNewsWire - 3 months ago

Genetron Health to present data at ESMO 2020 relating to precision oncology diagnostic development initiatives across lung, gastrointestinal and other cancer types, and to bioinformatics devel...

GlobeNewsWire - 3 months ago

Collaboration to pioneer “one-stop” R&D solutions to empower the full cycle of new drug development in oncology Collaboration to pioneer “one-stop” R&D solutions to empower the full cycle of n...

GlobeNewsWire - 4 months ago

BEIJING, Sept. 08, 2020 (GLOBE NEWSWIRE) -- Genetron Holdings Limited (“Genetron Health” or the “Company”, NASDAQ: GTH), a leading precision oncology platform company in China that specializ...

GlobeNewsWire - 4 months ago

BEIJING, Aug. 29, 2020 (GLOBE NEWSWIRE) -- Genetron Holdings Limited (“Genetron Health” or the “Company”, Nasdaq: GTH), a leading precision oncology platform company in China that specialize...

Forbes - 5 months ago

China accounts for more than 26% of the world's cancer deaths.

Bloomberg Markets and Finance - 5 months ago

Genetron CEO on Covid-19 Diagnostic Kits, Pandemic, Oncology

Sizhen Wang, co-founder and chief executive officer at Genetron Health, discusses developing diagnostic kits for Covid-19 which received approval for export from China, how the pandemic has ch...

GlobeNewsWire - 5 months ago

BEIJING, Aug. 06, 2020 (GLOBE NEWSWIRE) -- Genetron Holdings Limited (“Genetron Health” or the “Company”) (Nasdaq: GTH), a leading precision oncology company in China that specializes in off...

GlobeNewsWire - 5 months ago

BEIJING, July 29, 2020 (GLOBE NEWSWIRE) -- Genetron Holdings Limited (“Genetron Health” or the “Company”, NASDAQ:GTH), a leading precision oncology platform company in China that specializes...

GlobeNewsWire - 5 months ago

BEIJING, July 27, 2020 (GLOBE NEWSWIRE) -- Genetron Holdings Limited (“Genetron Health” or the “Company”, NASDAQ:GTH), a leading precision oncology company in China that specializes in offer...

GlobeNewsWire - 6 months ago

BEIJING, June 30, 2020 (GLOBE NEWSWIRE) -- Genetron Holdings Limited (“Genetron Health” or the “Company”, Nasdaq: GTH), a leading precision oncology platform company that covers full-cycle c...

Market Watch - 6 months ago

Genetron Holdings Ltd. gth shares rose 10% in their trading debut Friday, after the company's IPO priced above its price range.

Market Watch - 6 months ago

Genetron Holdings Ltd. priced its initial public offering at $16 per American depositary share, selling 16 million ADS to raise $256 million.

About GTH

Genetron Holdings Limited, a precision oncology company, engages in the cancer molecular profiling, and harnessing technologies in molecular biology and data science for cancer treatment. The company offers diagnosis and monitoring services, and early liver cancer screening services through laboratory developed tests services, such as HCCscreen, a proprietary assay for the early screening of liver cancer. It also provides in-vitro diagnostics products, including 8-gene Lung Cancer Assay, an IVD assay product based on semiconductor sequencing to... [Read more...]

Industry
Diagnostics & Research
IPO Date
Jun 19, 2020
Stock Exchange
NASDAQ
Ticker Symbol
GTH
Full Company Profile

Financial Performance

In 2019, GTH's revenue was 323.43 million, an increase of 43.63% compared to the previous year's 225.18 million. Losses were -676.03 million, 45.4% more than in 2018.

Financial numbers in millions CNY.
Financial Statements

Analyst Forecasts

According to 4 analysts, the average rating for GTH stock is "Strong Buy." The 12-month stock price forecast is 20.02, which is a decrease of -0.35% from the latest price.

Price Target
$20.02
(-0.35% downside)
Analyst Consensus: Strong Buy